Screener
Haemonetics HAE EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Haemonetics’s reported figures.
The source filing: Haemonetics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 6:09 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000313143-26-000120
FAQ
- What is Haemonetics's EBITDA?
- Haemonetics (HAE) reported EBITDA of $84.57M in Q2 2026.
- How has Haemonetics's EBITDA changed year-over-year?
- Haemonetics's EBITDA increased by 2.3% year-over-year, from $82.63M to $84.57M.
- What is the long-term trend for Haemonetics's EBITDA?
- Over 3 years (2022 to 2025), Haemonetics's EBITDA has grown at a 23.6% compound annual growth rate (CAGR), from $178.5M to $337.4M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Haemonetics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude